WuXi’s Pharmaceutical Development Services Division Merges with STA

We are excited to announce that WuXi subsidiary STA Pharmaceutical Co., Ltd. (STA)  has merged with our Pharmaceutical Development Services (PDS) division. The PDS division offers pre-formulation development, formulation development, as...

STA Signs Supply Agreement with TESARO

We are pleased to announce that STA Pharmaceutical Co., Ltd. (STA), a WuXi subsidiary, has signed a supply agreement with the oncology-focused biopharmaceutical company, TESARO, Inc. for certain starting and intermediate...

China Market Authorization Holder System Summit 2017 Recap

More than 300 professionals gathered at the recent China Marketing Authorization Holder (MAH) System Summit to learn from government agencies, life science research and drug development scientists, and drug development and...

WuXi Celebrates Partnerships & Innovation During BIO 2017 Cruise Around San Diego Bay

WuXi celebrated global innovation with hundreds of leaders from biotech, pharma, research institutions, and the venture capital community who attended BIO 2017 during a private cruise reception around San Diego Bay on...

WuXi NextCODE AI Points to New Therapeutic Approaches to Cardiovascular Disease and Cancer in...

We are thrilled about WuXi NextCODE's contribution of its artificial intelligence (AI) and sequencing teams to the discovery of a novel mechanism regulating how blood vessels grow. The study, 'FGF-dependent metabolic control...

SPOTLIGHT

STAY CONNECTED

Twitter LinkedIn 

INNOVATION THAT MATTERS

A Futuristic Biopharma Company Addressing Some of the World’s Biggest Health...

By Rich Soll, Senior Advisor, Strategic Initiatives at WuXi AppTec (@richsollwx) For the past few years, PureTech Health has been building a new R&D model for advancing breakthrough...